Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients

Pharmacological Research

Volumn 54, Issue 2, 2006, Pages 142-149

  Ferrari, Anna ^a   Savino, Gustavo ^a   Gallesi, Daniela ^a   Pinetti, Diego ^a   Bertolini, Alfio ^a   Sances, Grazia ^b   Coccia, Ciro Pio Rosario ^a   Pasciullo, Gabriella ^a   Leone, Sheila ^c   Loi, Marianna ^b   Sternieri, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Caffeine; Indomethacin; Medication overuse headache; Pharmacokinetics; Prochlorperazine

Indexed keywords

CAFFEINE; INDOMETACIN; PROCHLORPERAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC PAIN; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MISUSE; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HABIT; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MIGRAINE; ORGAN INJURY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SUPPOSITORY; TABLET;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHRONIC DISEASE; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HEADACHE DISORDERS; HEADACHE DISORDERS, SECONDARY; HUMANS; INDOMETHACIN; MIDDLE AGED; PROCHLORPERAZINE; TIME FACTORS;

EID: 33745938770     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.03.022     Document Type: Article

References (50)

1. Italian Society for the Study of Headaches. Ad Hoc Committee for the diagnostic and therapeutic guidelines for migraine and cluster headache. J Headache Pain 2 (2001) 1-192
2. Sicuteri F., and Nicolodi M. The holistic hypothesis of migraine. Ann Ital Med Int 12 Suppl 1 (1997) 3-32
3. Lockie L.M. Long-term experience with indomethacin in active stages of moderate to severe rheumatoid arthritis and moderate to severe osteoarthritis. Semin Arthritis Rheum 12 (1982) 109-111
4. Dodick D.W. Indomethacin-responsive headache syndromes. Curr. Pain Headache Rep 8 (2004) 19-26
5. Hu X.H., Tang H.W., Li Q.S., and Huang X.F. Central mechanism of indomethacin analgesia. Eur J Pharmacol 263 (1994) 53-57
6. Nitter W.H., Johnsen L.F., and Eriksen M. Acute effects of indomethacin on cerebral blood flow in man. Pharmacology 51 (1995) 48-55
7. Buzzi M.G., Sakas D.E., and Moskovitz M.A. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura madre. Eur J Pharmacol 165 (1989) 252-258
8. Olver I.N., Webster L.K., Bishop J.F., Clarke J., and Hillcoat B.L. A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. Eur J Cancer Clin Oncol 25 (1989) 1457-1461
9. Zhang W.Y. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf 24 (2001) 1127-1142
10. Ghelardini C., Galeotti N., and Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 590-595
11. Matthew R.J., and Wilson W.H. Caffeine consumption, withdrawal and cerebral blood flow. Headache 25 (1985) 305-309
12. Galeotti N., Ghelardini C., Grazioli I., and Uslenghi C. Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in "in vivo" models of migraine. Pharmacol Res 46 (2002) 245-250
13. Di Monda V., Nicolodi M., Aloisio A., Del Bianco P., Fonzari M., Grazioli I., et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache 43 (2003) 835-844
14. Ferrari A., Pasciullo G., Savino G., Cicero A.F.G., Ottani A., Bertolini A., et al. Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study. Cephalalgia 24 (2004) 356-362
15. Emori H.W., Paulus H., Bluestone R., Champion D.G., and Pearson C. Indomethacin serum concentrations in man. Ann Rheum Dis 35 (1976) 333-338
16. Castillo J., Munoz P., Guitera V., and Pascual J. Epidemiology of chronic daily headache in the general population. Headache 39 (1999) 190-196
17. Bigal M.E., Sheftell F.D., Rapoport A.M., Tepper S.J., and Lipton R.B. Chronic daily headache: identification of factors associated with induction and transformation. Headache 42 (2002) 575-581
18. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004; 24(Suppl 1):9-160.
19. Fields H., and Heinricher M. Brainstem modulation of nociceptor-driven withdrawal reflexes. Ann N Y Acad Sci 563 (1989) 34-44
20. Srikiatkhachorn A., Tarasub N., and Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 40 (2000) 343-350
21. Avgerinos A., and Malamataris S. High performance liquid chromatographic determination of indomethacin in human plasma and urine. J Chromatogr 495 (1989) 309-313
22. Fowler A., Taylor W., and Bateman D.N. Plasma prochlorperazine assay by high-performance liquid chromatography-electrochemistry. J Chromatogr 380 (1986) 202-205
23. Kintz P., Lamant J.M., and Mangin P. Ultra-rapid high performance liquid chromatographic screening for phenothiazines in human samples. Analyst 115 (1990) 1269-1270
24. Normann G., and Streiner D. Biostatistics. The bare essentials. 2nd ed. (2000), B.C. Decker Inc., Ontario, Canada pp. 89-162
25. Schuster V., von Stockhausen H.B., and Seyberth H.W. Effects of highly overdosed indomethacin in a preterm infant with symptomatic patent ductus arteriosus. Eur J Pediatr 146 (1990) 651-653
26. Duggan D.E., Hogans A.F., Kwan K.C., and McMahon F.G. The metabolism of indomethacin in man. J Pharmacol Exp Ther 181 (1972) 563-575
27. Emori H.W., Champion D.G., Bluestone R., and Paulus H.E. Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis 32 (1973) 433-435
28. Nakajima M., Inoue T., Shimada N., Tokudome S., Yamamoto T., and Kuroiwa Y. Cytochrome P4502C9 catalyzes indomethacin. O-demethylation in human liver microsomes. Drug Metab Dispos 26 (1998) 261-266
29. Duggan D.E., Hooke K.F., Noll R.M., and Kwan C.K. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 24 (1975) 1749-1754
30. Kwan K.C., Breault G.O., Umbenhauer E.R., McMahon F.G., and Duggan D.E. Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm 4 (1976) 255-280
31. Yeh K.C. Indomethacin and indomethacin sustained release-a comparison of their pharmacokinetic profiles. Semin Arthritis Rheum 12 (1982) 136-141
32. Holt L.P.J., and Hawkins C.F. Indomethacin: studies of absorption and of the use of indomethacin suppositories. Br Med J 1 (1965) 1354-1356
33. Hvidberg E., Lausen H.H., and Jansen J.A. Indomethacin: plasma concentrations and protein binding in man. Eur J Clin Pharmacol 4 (1972) 119-124
34. Alvan G., Orme M., Bertillsson L., Ekstrand R., and Palmer L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18 (1975) 364-373
35. Kuang C., and Yeh K.C. Pharmacokinetic overview of indomethacin and sustained-release indomethacin. Am J Med 79 (1985) 3-12
36. Renner E., Wietholtz H., Hunguenin P., Arnaud M.J., and Preisig R. Caffeine: a model compound for measuring liver function. Hepatology 4 (1984) 38-46
37. Bonati M., Latini R., Galletti F., Young J.F., Tognoni G., and Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 32 (1982) 98-106
38. Blanchard J., and Sawers S.J.A. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm 11 (1983) 109-126
39. Kaplan G.B., Greenblatt D.J., Ehrenberg B.L., Goddard J.E., Cotreau M.M., Harmatz J.S., et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37 (1997) 693-703
40. Regal K.A., Kunze K.L., Peter R.M., and Nelson S.D. Oxidation of caffeine by CYP1A2: isotope effects and metabolic switching. Drug Metab Dispos 33 (2005) 1837-1844
41. Rodrigues A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug Metab Dispos 33 (2005) 1567-1575
42. Linnet K., and Wiborg O. Steady state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 60 (1996) 41-47
43. Armstrong E.P., and Malone D.C. The impact of nonsteroidal antiinflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 25 (2003) 1-8
44. Garcia Rodriguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
45. Bannwarth B., Netter P., Lapicque F., Péré P., Thomas P.H., and Gaucher A. Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Eur J Clin Pharmacol 38 (1990) 343-346
46. Nilsson F., Bjorkman S., Rosén I., Messeter K., and Nordstrom C.H. Cerebral vasoconstriction by indomethacin in intracranial hypertension. Anesthesiology 83 (1995) 1283-1292
47. Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe?. Acta Anaesthesiol Scand 49 (2005) 341-350
48. Asmark H., Lundberg P.O., and Olsson S. Drug-related headache. Headache 29 (1989) 441-444
49. Wang S.J., Fuh J.L., Young Y.H., Lu S.R., and Shia B.C. Frequency and predictors of physician consultations for headache. Cephalalgia 21 (2001) 25-30
50. Isah A.O., Rawlins M.D., and Bateman D.N. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol 32 (1991) 677-684